Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 693 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Dermatitis Clear all
Not listed Phase 2 Interventional

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

NCT05694884
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, ASLAN004
Drug
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Birmingham, Alabama • Encino, California • Fountain Valley, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Randomized Controlled Trial of an Eczema Care Plan

NCT02251340
View directory record Official record
Conditions
Eczema
Interventions
Eczema Care Plan
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 2 Interventional

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

NCT07660835
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
6 Months to 23 Months
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

NCT00703573
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
S-777469 400 mg, S-777469 800 mg, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

NCT02651714
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
28
States / cities
Encinitas, California • Encino, California • Lomita, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

NCT02932891
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DSXS topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting No phase listed Observational

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

NCT00177268
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema, Atopic Dermatitis
Interventions
Blood draw, skin biopsy or urine collection
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT04250350
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • North Little Rock, Arkansas • Canoga Park, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

NCT05142774
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
102
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 4 Interventional

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

NCT00460083
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream
Drug · Device
Lead sponsor
Ceragenix Pharmaceuticals
Industry
Eligibility
2 Years to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
San Diego, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2008 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study to Test the Effects of Arctiva on Mild to Moderate Eczema

NCT05918237
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Arctiva
Other
Lead sponsor
ClinOhio Research Services, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

NCT04417894
View directory record Official record
Conditions
Moderate to Severe Atopic Hand and Foot Dermatitis
Interventions
dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Birmingham, Alabama • Redwood City, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 20, 2026, 5:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis

NCT00691366
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

NCT04804605
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
76
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Not listed No phase listed Observational

A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients

NCT04699695
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Biologic therapy versus no biologic therapy
Other
Lead sponsor
DermTech
Other
Eligibility
1 Year and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
No Longer Available No phase listed Expanded access

Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

NCT04564755
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
21
States / cities
Birmingham, Alabama • Lancaster, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 20, 2026, 5:38 PM EDT
Terminated No phase listed Observational

Dupilumab Phase 4 Study

NCT03411837
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Biological
Lead sponsor
Northwestern University
Other
Eligibility
12 Years and older
Enrollment
46 participants
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 20, 2026, 5:38 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

An Investigation of a Multi-Function Skincare Product to Improve Aging, Eczema, and Acne Outcomes

NCT05873933
View directory record Official record
Conditions
Acne, Eczema, Skin Aging
Interventions
Hemptress Oil
Other
Lead sponsor
Hemptress
Industry
Eligibility
21 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05704738
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 17 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
98
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis

NCT02347176
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
24
States / cities
Phoenix, Arizona • Rogers, Arkansas • Fremont, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting No phase listed Observational

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

NCT00568997
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

NCT06238817
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Little Rock, Arkansas • Fountain Valley, California • Fremont, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

NCT04140695
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
51
States / cities
Hoover, Alabama • Tempe, Arizona • Encino, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 20, 2026, 5:38 PM EDT